Vertex's CF drugs are bringing in billions of dollars in revenue, and in recent years the company has also expanded into ...
The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering ...
Venture capital firm Portal Innovations is planning to open a 30,000-square-foot science incubator in Salt Lake City while ...
With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter, ...
The companies Vaxcyte, Generate Biomedicines, and Immunic bagged the biggest biotech funding rounds overall in February 2026.
Investors are increasingly wary of the rare-disease space, spooked by a regulatory shift.
Tomorrow BioTech and Green2Gold unite to support biotech and green innovators with labs, mentorship, and a path to ...
T-cell engager (TCE) specialist Candid Therapeutics has entered into a reverse merger agreement with Rallybio that will allow ...
Laboratory real estate has endured high vacancy amid thin funding for the biotech business in recent years. Those conditions ...
The AI drug discovery specialist is the fifth biotechnology company to go public in February and priced the sector’s largest ...
February 2026 saw a major biopharma acquisition, four key buyouts, and licensing deals in antibodies, small molecules, and ...
X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results